Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Why Investors Should Not Take a Ride on Virgin Galactic

By Larry Ramer, InvestorPlace Contributor

Among the challenges facing SPCE stock at this point are very tough competition and an upcoming test flight.

3 Consumer Cyclical Stocks to Buy for the Coming Travel Explosion

By Larry Ramer, InvestorPlace Contributor

Consumer cyclical stocks should expect a big boost from the CDC's recent announcement that vaccinated people can resume daily activities.

Why the Outlook of FuboTV Remains Bleak

By Larry Ramer, InvestorPlace Contributor

I continue to believe that FuboTV's addressable market is quite low. Meanwhile, its losses are mounting. Consequently, I remain bearish on FUBO stock.

Hyliion Stock Has a Good Story, but It’s Too Risky at These Prices

By Larry Ramer, InvestorPlace Contributor

There's a great deal to like about Hyliion, but the risk-reward ratio of HYLN stock is negative at this point.

Ocugen Stock Is Left Behind As the U.S. Emerges From the Pandemic

By Larry Ramer, InvestorPlace Contributor

There seems to be no need for Covaxin in the U.S. and there are no indications that the U.S. is considering approving it. Consequently, OCGN stock is worth shorting.

Load More